China Shineway Pharmaceutical Group Limited (C1S) - Total Assets
Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (C1S) holds total assets worth €10.78 Billion EUR (≈ $12.60 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
China Shineway Pharmaceutical Group Limited - Total Assets Trend (2013–2025)
This chart illustrates how China Shineway Pharmaceutical Group Limited's total assets have evolved over time, based on quarterly financial data. Also see China Shineway Pharmaceutical Group Limi market cap and net worth for the company's overall valuation and market capitalisation.
China Shineway Pharmaceutical Group Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
China Shineway Pharmaceutical Group Limited's total assets of €10.78 Billion consist of 86.3% current assets and 13.7% non-current assets. Review China Shineway Pharmaceutical Group Limi debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 66.7% |
| Accounts Receivable | €805.93 Million | 7.5% |
| Inventory | €691.30 Million | 6.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €15.72 Million | 0.2% |
| Goodwill | €165.96 Million | 1.5% |
Asset Composition Trend (2013–2025)
This chart illustrates how China Shineway Pharmaceutical Group Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See China Shineway Pharmaceutical Group Limi (C1S) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China Shineway Pharmaceutical Group Limited's current assets represent 86.3% of total assets in 2025, an increase from 67.6% in 2013.
- Cash Position: Cash and equivalents constituted 66.7% of total assets in 2025, up from 39.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 7.5% of total assets.
China Shineway Pharmaceutical Group Limited Competitors by Total Assets
Key competitors of China Shineway Pharmaceutical Group Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
China Shineway Pharmaceutical Group Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.71 | 3.51 | 4.62 |
| Quick Ratio | 3.43 | 3.18 | 4.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €6.79 Billion | €6.15 Billion | €4.32 Billion |
China Shineway Pharmaceutical Group Limited - Advanced Valuation Insights
This section examines the relationship between China Shineway Pharmaceutical Group Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.74 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 7.3% |
| Total Assets | €10.78 Billion |
| Market Capitalization | $736.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values China Shineway Pharmaceutical Group Limited's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: China Shineway Pharmaceutical Group Limited's assets grew by 7.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for China Shineway Pharmaceutical Group Limited (2013–2025)
The table below shows the annual total assets of China Shineway Pharmaceutical Group Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €10.78 Billion ≈ $12.60 Billion |
+7.33% |
| 2024-12-31 | €10.04 Billion ≈ $11.74 Billion |
+4.88% |
| 2023-12-31 | €9.57 Billion ≈ $11.19 Billion |
+16.30% |
| 2022-12-31 | €8.23 Billion ≈ $9.62 Billion |
+14.27% |
| 2021-12-31 | €7.20 Billion ≈ $8.42 Billion |
-0.13% |
| 2020-12-31 | €7.21 Billion ≈ $8.43 Billion |
+1.15% |
| 2019-12-31 | €7.13 Billion ≈ $8.34 Billion |
+5.94% |
| 2018-12-31 | €6.73 Billion ≈ $7.87 Billion |
+1.00% |
| 2017-12-31 | €6.67 Billion ≈ $7.79 Billion |
+3.09% |
| 2016-12-31 | €6.47 Billion ≈ $7.56 Billion |
+5.07% |
| 2015-12-31 | €6.15 Billion ≈ $7.19 Billion |
+4.16% |
| 2014-12-31 | €5.91 Billion ≈ $6.91 Billion |
+2.95% |
| 2013-12-31 | €5.74 Billion ≈ $6.71 Billion |
-- |
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more